CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Hormone Replacement Therapy

Hormone replacement therapy (HRT) is any form of hormone therapy wherein the patient, in the course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones or to substitute other hormones for naturally occurring hormones. Common forms of HRT include:

  • Menopausal hormone therapy is based on the idea that the treatment may prevent discomfort caused by diminished circulating estrogen and progesterone hormones, or in the case of the surgically or prematurely menopausal, that it may prolong life and may reduce incidence of dementia. It involves the use of one or more of a group of medications designed to artificially boost hormone levels. The main types of hormones involved are estrogen, progesterone, or progestins, and sometimes, testosterone. It is often referred to as "treatment" rather than therapy.
  • Transgender hormone therapy introduces hormones associated with the gender that the patient identifies with (notably testosterone for transgender men and estrogen for transgender women). Some intersex people may also receive HRT. Cross-sex hormone treatment for transgender individuals is divided into two main types: feminizing hormone therapy and masculinizing hormone therapy.

Androgen replacement therapy (andropausal and ergogenic use) is a hormone treatment often prescribed to counter the effects of male hypogonadism or the "andropause". It is also prescribed to lessen the effects or delay the onset of normal male aging. Additionally, androgen replacement therapy is used for men who have lost their testicular function to disease, cancer, or other causes.

As recently as 2005, women have had a positive attitude towards HRT, but based on the empirical data, these attitudes may be overly optimistic. There is still much to learn about how HRT affects people. In the combined hormone trial, the WHI tested only one estrogen (Premarin) and one progestin (Provera), in a single pill (Prempro), at a single dose (0.625 mg Premarin and 2.5 mg Provera). Therefore, the results are not reliable nor representative.

To avoid HRT risks, it is essential to use the most effective delivery method of both estrogen and progesterone. Bioidentical estradiol (estrogen) when taken orally is converted in the liver to estrone, a weaker bioidentical estrogen. However, when estrogen as estradiol is used transdermally as a patch, gel, or pessary, it enters the bloodstream as bioidentical estradiol. When estrogen is ingested it is subjected to first pass metabolism (Phase I drug metabolism) and is processed through the liver. This first pass metabolism stimulates proteins associated with heart disease and stroke, such as C-reactive protein, activated protein C, and clotting factors. Using a patch, gel, or pessary to take estrogen avoids first pass metabolism and the risks associated with it and the same level of blood concentration can be achieved avoiding the serious side effects associated with oral estradiol HRT. Current research shows that the transdermal route of estradiol administration can also be advantageous for women with diabetes, hypertension and other cardiovascular risk factors, as those risks increase with advancing age. Women taking bioidentical estrogen, orally or transdermally, who have a uterus should still take a progesterone to lower the risk of endometrial cancer. The plant-derived progesterone creams sold over the counter contain too little progesterone to be effective. Wild yam extract creams are not effective since the natural progesterone present in the extract is not bioavailable.

Past research has highlighted potential risks of HRT. The principal results from the Women's Health Initiative Randomized Controlled Trial was that hazard rate of invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits.

A study where women going through menopause using HRT with Progestin as a major component of the therapy showed a few adverse effects on hearing, which highlights the importance of choosing bioidentical progesterone instead of synthetic progestin. Not only does the Progestin decrease the functionality of many regions of the ear it also reduces the effectiveness in parts of the central nervous system used for hearing. Also, in some situations, it has been shown that menopausal women who are caregivers and receive HRT can have an increased chance for cardiovascular issues. As caregivers, it is implied that they have more acute stress in their lives and that acute stress along with the HRT is priming negative cardiovascular effects.

Recent research done by the Million Women Study, funded by Cancer Research UK has proven that certain forms of HRT increase the risk of endometrial (womb) cancer. However, previous research has shown that the combined type of HRT poses a greater breast cancer risk than tibolone or oestrogen (estradiol)-only HRT and, because breast cancer is more common than endometrial cancer, the researchers believe that when considering the overall effect of HRT it is important to look at both breast and endometrial cancer. However, this study was conducted using oral estradiol instead of transdermal estradiol which avoids the risks which the study highlights. Again, this shows that the combined estrogen patch (such as Evorel® Conti) or gel (ESTROGEL PROPAK™ - 17ß-estradiol and micronized progesterone) is the preferable treatment choice.

The Society of Obstetricians and Gynaecologists of Canada recommends Transdermal Estrogen and Micronized Progesterone as a first line hormone therapy option stating that the overall benefits of this therapy include reduction of vasomotor symptoms (hot flashes), lower risk of osteoporotic fractures, lessening of urogenital atrophy, lowering somatic pain and arthralgia, lowering the risk of colorectal cancer and mood stabilization.

There is a structural difference between hormone therapies that are bioidentical and those that are non-bioidentical, as non-bioidentical are responsible for side effects and health risks in humans. However, they can have positive health benefits for women, and bioidentical hormones can be customized from individual to individual.

HRT has been shown to have other beneficial effects. In a study women taking estrogen through HRT showed that the estrogen positively affects the prefrontal cortex by boosting the working memory. This suggests that estrogen may play a key role in certain frontal lobe functions in women. Women using HRT after menopause have no additional weight gain compared to women who do not use HRT. Also women who use HRT with an estrogen component show positive effects in their sex life (mainly increasing their libido and sexual sensitivity) but the effects are inconsistent across women. These sexual improvements may dissipate after receiving some forms of HRT for extended periods of time.

  • Hormone Replacement Therapy

  • Hormone replacement therapy

    facebook Share on Facebook

    Hormone replacement therapy (HRT) is any form of hormone therapy wherein the patient, in the course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones or to substitute other hormones for naturally occurring hormones. Common forms of HRT include:

    • Menopausal hormone therapy is based on the idea that the treatment may prevent discomfort caused by diminished circulating estrogen and progesterone hormones, or in the case of the surgically or prematurely menopausal, that it may prolong life and may reduce incidence of dementia. It involves the use of one or more of a group of medications designed to artificially boost hormone levels. The main types of hormones involved are estrogen, progesterone, or progestins, and sometimes, testosterone. It is often referred to as "treatment" rather than therapy.
    • Transgender hormone therapy introduces hormones associated with the gender that the patient identifies with (notably testosterone for transgender men and estrogen for transgender women). Some intersex people may also receive HRT. Cross-sex hormone treatment for transgender individuals is divided into two main types: feminizing hormone therapy and masculinizing hormone therapy.

    Androgen replacement therapy (andropausal and ergogenic use) is a hormone treatment often prescribed to counter the effects of male hypogonadism or the "andropause". It is also prescribed to lessen the effects or delay the onset of normal male aging. Additionally, androgen replacement therapy is used for men who have lost their testicular function to disease, cancer, or other causes.

  • Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. 📎

    facebook Share on Facebook
    Abstract Title:

    Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients.

    Abstract Source:

    Reprod Biol Endocrinol. 2011;9:26. Epub 2011 Feb 18. PMID: 21332999

    Abstract Author(s):

    Anna Maria Aloisi, Ilaria Ceccarelli, Maria Carlucci, Annalisa Suman, Gianfranco Sindaco, Sergio Mameli, Valentina Paci, Laura Ravaioli, Giandomenico Passavanti, Valeria Bachiocco, Gilberto Pari

    Article Affiliation:

    Department of Physiology, Section of Neuroscience and Applied Physiology, University of Siena, Siena, Italy. This email address is being protected from spambots. You need JavaScript enabled to view it.

    Abstract:

    BACKGROUND:In male patients suffering from chronic pain, opioid administration induces severe hypogonadism, leading to impaired physical and psychological conditions such as fatigue, anaemia and depression. Hormone replacement therapy is rarely considered for these hypogonadic patients, notwithstanding the various pharmacological solutions available.

    METHODS:To treat hypogonadism and to evaluate the consequent endocrine, physical and psychological changes in male chronic pain patients treated with morphine (epidural route), we tested the administration of testosterone via a gel formulation for one year. Hormonal (total testosterone, estradiol, free testosterone, DHT, cortisol), pain (VAS and other pain questionnaires), andrological (Ageing Males' Symptoms Scale-AMS) and psychological (POMS, CES-D and SF-36) parameters were evaluated at baseline (T0) and after 3, 6 and 12 months (T3, T6, T12 respectively).

    RESULTS:The daily administration of testosterone increased total and free testosterone and DHT at T3, and the levels remained high until T12. Pain rating indexes (QUID) progressively improved from T3 to T12 while the other pain parameters (VAS, Area%) remained unchanged. The AMS sexual dimension and SF-36 Mental Index displayed a significant improvement over time.

    CONCLUSIONS:In conclusion, our results suggest that a constant, long-term supply of testosterone can induce a general improvement of the male chronic pain patient's quality of life, an important clinical aspect of pain management.

  • Is migraine a consequence of a loss of neurohormonal and metabolic integrity? A new hypothesis.

    facebook Share on Facebook
    Abstract Title:

    Is migraine a consequence of a loss of neurohormonal and metabolic integrity? A new hypothesis.

    Abstract Source:

    Neuro Endocrinol Lett. 2015 ;36(5):421-9. PMID: 26707041

    Abstract Author(s):

    Sergey A Dzugan, Konstantine S Dzugan

    Article Affiliation:

    Sergey A Dzugan

    Abstract:

    OBJECTIVE:In 2002 we suggested a new hypothesis of migraine. This hypothesis implies that migraine is a consequence of a loss of neurohormonal and metabolic integrity. The goal of this clinical analysis is to present the evaluation of the effect of a multimodal treatment program in migraine management.

    MATERIAL AND METHODS:We evaluated 30 patients ages 16-66 with migraine who were treated with a multimodal treatment program. All patients received a complex program which included: hormonorestorative therapy (HT) with bio-identical hormones; correction of balance between sympathetic and parasympathetic systems and simultaneously calcium/magnesium balance;"resetting"the pineal gland; improvement of intestinal absorption through restoration of normal intestinal flora, and a cleanse from parasitic infestation (if necessary). Serum levels of total cholesterol (TC), pregnenolone, dehydroepiandrosterone sulfate (DHEAS), progesterone, total estrogen, and total testosterone were determined,

    RESULTS:All patients responded to this regimen. We do not have patients who still have migraine after they started to use this program. Laboratory finding prior to HT showed the significant deficiency in production of all basic steroid hormones (progesterone and pregnenolone production declined the most). Concurrent symptoms such as fibromyalgia, insomnia, depression, gastrointestinal disorders, and fatigue had disappeared. Total cholesterol completely normalized in 22 (91.7%) patients. No adverse effects or complications related to this program were registered.

    CONCLUSIONS:Our findings support the hypothesis that migraine is a consequence of a loss of neurohormonal and metabolic integrity, and that migraine can be managed by a multimodal approach.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.